India Globalization Capital (NYSE American: IGC) this morning announced the launching of two new websites (www.IGCPharma.com and www.Hyalolex.com) to detail its initiatives, development timeline and pipeline of pharmaceutical cannabinoids for use in treatment of the symptoms of Alzheimer’s disease, pain, seizures and other health-related issues. Ram Mukunda, CEO of IGC, indicated in the news release that Alzheimer’s is IGC’s initial focus on the canna-pharmaceutical front and that the company’s near-term goal is to commercialize its Alzheimer’s liquid formulation as a Complimentary and Alternative Medicine (“CAM”) and sell the product through licensed medical cannabis dispensaries in the U.S., Canada and Germany. Mukunda indicated that longer-term goals include moving IGC’s Alzheimer’s formulation through FDA registered pre-clinical and clinical trials. IGC also has six provisional patent filings for phytocannabinoid-based combination therapy for the indications of pain, medical refractory epilepsy, and cachexia. Further, in May 2017, IGC acquired exclusive rights to a University of South Florida Research Foundation filed patent entitled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.”
To view the full press release, visit http://cnw.fm/RnF1q
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information, please visit www.IGCinc.us.
More from CannabisNewsBreaks
About HempWire
HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
Turning Point Brands (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, recently…
WEED Inc. (OTCQB: BUDZ), a global cannabis and hemp bioresearch company based in the U.S.,…
Flora (NASDAQ: FLGC) has closed a registered direct offering to institutional investors for the aggregate…
Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced its plans to host a Spaces call…
CBD Life Sciences (OTC: CBDL) today announced its potential for explosive profits in a $70…
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that…